Dermatology Update 2016


Montréal, Le Centre Sheraton - NOVEMBER 3-6, 2016

The Stuart Maddin Lecture Series

The evolution of modern psoriasis management

Psoriasis management has been revolutionised by a translational approach whereby insights into its pathogenesis have delivered effective targeted therapies. These are exemplified by the recent introduction of anti-IL17 biologics and oral small molecules into clinical practice and the impending introduction of anti-IL23 biologics. Long-term real world safety of biologics and other systemic therapies for psoriasis is paramount and can be answered by pharmacovigilance registries such as the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Medicine in general, and the management of psoriasis is no exception, is moving away from the old-fashioned reactive empirical model to one that is both stratified and proactive.  The objective is that a patient with psoriasis (whatever its severity) will be placed onto the right treatment pathway first time. Such a pathway will encompass the right drug coupled to bespoke lifestyle advice that accounts for comorbidities including psoriatic arthritis and cardiovascular disease.

Globally it important that people with psoriasis, wherever they reside in the world, have access to the best available care; this can only be achieved by understanding the prevalence and burden of the disease  via initiatives such as the Global Psoriasis Atlas.


Prof. Christopher Griffiths

Prof. Christopher Griffiths

Dermatologist, Manchester, United Kingdom